Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma - Summary - MDSpire

Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma

  • By

  • Chunxiao Ni

  • Jiaju Xu

  • Yu Pang

  • June 10, 2026

  • 0 min

Share

Objective:

To correct the authorship of the original article regarding the omission of Jiaju Xu as an equal contributing author.

Key Findings:
  • Jiaju Xu was omitted as an equal contributing author in the original publication.
Interpretation:

Conclusion:

The article has been updated to reflect the correct authorship.

Sources:

Original Source(s)

Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma

  • by Chunxiao Ni, Jiaju Xu, Yu Pang

  • June 10, 2026

Related Content

BCOR-CCNB3 fusion–positive sarcoma treated with chemotherapy and carbon-ion radiotherapy: a case report of long-term disease control of a cervical spine case with a 12-year follow-up

Survival benefit of extended lymphadenectomy in endometrial cancer: a meta-analysis with risk-stratified subgroup analysis

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

  • June 9, 2026

  • 5 min